GlassScriptPhysician profile
Darrell W Wong
NPI 1265446686
$11,387.60
in general payments reported to CMS, 2019-2025
38 companies · $2,687 in 2025
The $2,687 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $762 · 2021: $1,879 · 2022: $1,985 · 2023: $1,614 · 2024: $1,754 · 2025: $2,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,839 · Consulting Fee: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,839.26 |
| Consulting Fee | $215.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,039.54 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $1,154.91 | 2019-2025 | Hizentra, Haegarda, Privigen |
| Astrazeneca Pharmaceuticals LP | $1,101.00 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $943.46 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $767.56 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $609.96 | 2020-2025 | Xembify |
| Genzyme Corporation | $559.51 | 2019-2025 | |
| Genentech USA, INC. | $553.02 | 2019-2025 | Xolair |
| Kaleo, INC. | $505.04 | 2019-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $431.23 | 2019-2025 | |
| Pfizer INC. | $413.03 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $331.41 | 2021-2025 | Orladeyo |
| Adma Biomanufacturing LLC | $249.25 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.36 | 2019-2023 | |
| Optinose US, INC. | $158.10 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $130.95 | 2025 | Neffy |
| Blueprint Medicines Corporation | $130.46 | 2023-2024 | Ayvakit |
| Pharming Healthcare, INC. | $121.37 | 2019-2023 | Ruconest |
| Amgen INC. | $106.35 | 2022-2025 | Tezspire |
| Incyte Corporation | $106.29 | 2021-2025 | Opzelura |
| Organon LLC | $87.64 | 2025 | Vtama, Nexplanon |
| Covis Pharma Gmbh | $75.38 | 2021 | |
| Abbvie INC. | $72.35 | 2022-2023 | Rinvoq |
| Galderma Laboratories, L.P. | $63.68 | 2025 | Nemluvio |
| Gc Biopharma USA, INC. | $63.45 | 2024-2025 | Alyglo, Alyglo |
| Shire North American Group INC | $56.80 | 2019 | |
| Leo Pharma INC. | $40.98 | 2022-2025 | Adbry |
| Kedrion Biopharma, INC. | $38.69 | 2024 | Gammaked, Koate, Albuked |
| Alk-Abello, INC | $36.38 | 2022 | |
| Aimmune Therapeutics, INC. | $32.52 | 2022 | |
| Lilly USA, LLC | $31.65 | 2025 | Ebglyss |
| Eyevance Pharmaceuticals LLC | $29.95 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $27.11 | 2023 | |
| Cycle Pharmaceuticals INC | $25.95 | 2025 | Sajazir |
| Greer Laboratories, INC. | $23.84 | 2025 | Palforzia |
| Sanofi-Aventis U.S. LLC | $22.91 | 2019 | |
| Inspire Medical Systems, INC. | $21.06 | 2023 | Inspire |
| Teva Pharmaceuticals USA, INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrell Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.